275 related articles for article (PubMed ID: 25749844)
1. Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity.
Karimi K; Karimi Y; Chan J; Boudreau JE; Basset J; Chew MV; Reid S; Bramson JL; Wan Y; Ashkar AA
Innate Immun; 2015 Aug; 21(6):626-34. PubMed ID: 25749844
[TBL] [Abstract][Full Text] [Related]
2. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
3. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
5. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.
Vujanovic L; Szymkowski DE; Alber S; Watkins SC; Vujanovic NL; Butterfield LH
Blood; 2010 Jul; 116(4):575-83. PubMed ID: 20430958
[TBL] [Abstract][Full Text] [Related]
6. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.
Boudreau JE; Stephenson KB; Wang F; Ashkar AA; Mossman KL; Lenz LL; Rosenthal KL; Bramson JL; Lichty BD; Wan Y
Cancer Res; 2011 Apr; 71(7):2497-506. PubMed ID: 21307131
[TBL] [Abstract][Full Text] [Related]
7. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
10. Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells.
Capobianco A; Rovere-Querini P; Rugarli C; Manfredi AA
Int J Cancer; 2006 Dec; 119(12):2861-9. PubMed ID: 16998790
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
[TBL] [Abstract][Full Text] [Related]
12. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
[TBL] [Abstract][Full Text] [Related]
13. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs.
Morandi B; Mortara L; Carrega P; Cantoni C; Costa G; Accolla RS; Mingari MC; Ferrini S; Moretta L; Ferlazzo G
Int Immunol; 2009 May; 21(5):599-606. PubMed ID: 19325034
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell and NK cell reciprocal cross talk promotes gamma interferon-dependent immunity to blood-stage Plasmodium chabaudi AS infection in mice.
Ing R; Stevenson MM
Infect Immun; 2009 Feb; 77(2):770-82. PubMed ID: 19015248
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity.
Yamaguchi S; Tatsumi T; Takehara T; Sasakawa A; Hikita H; Kohga K; Uemura A; Sakamori R; Ohkawa K; Hayashi N
Cancer Immunol Immunother; 2008 Dec; 57(12):1861-9. PubMed ID: 18438665
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
17. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells.
Koka R; Burkett P; Chien M; Chai S; Boone DL; Ma A
J Immunol; 2004 Sep; 173(6):3594-8. PubMed ID: 15356102
[TBL] [Abstract][Full Text] [Related]
19. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection.
Jinushi M; Takehara T; Tatsumi T; Kanto T; Groh V; Spies T; Suzuki T; Miyagi T; Hayashi N
J Immunol; 2003 Nov; 171(10):5423-9. PubMed ID: 14607946
[TBL] [Abstract][Full Text] [Related]
20. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells.
Shimizu K; Asakura M; Fujii S
J Immunol; 2011 May; 186(10):5927-37. PubMed ID: 21460206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
